Associations with age and glomerular filtration rate in a referred population with chronic kidney disease: methods and baseline data from a UK multicentre cohort study (NURTuRE-CKD).
albuminuria
chronic kidney disease
cohort study
risk profile
sex
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
12
02
2023
medline:
2
11
2023
pubmed:
26
5
2023
entrez:
25
5
2023
Statut:
ppublish
Résumé
Chronic kidney disease (CKD) is common but heterogenous and is associated with multiple adverse outcomes. The National Unified Renal Translational Research Enterprise (NURTuRE)-CKD cohort was established to investigate risk factors for clinically important outcomes in persons with CKD referred to secondary care. Eligible participants with CKD stages G3-4 or stages G1-2 plus albuminuria >30 mg/mmol were enrolled from 16 nephrology centres in England, Scotland and Wales from 2017 to 2019. Baseline assessment included demographic data, routine laboratory data and research samples. Clinical outcomes are being collected over 15 years by the UK Renal Registry using established data linkage. Baseline data are presented with subgroup analysis by age, sex and estimated glomerular filtration rate (eGFR). A total of 2996 participants was enrolled. Median (interquartile range) age was 66 (54-74) years, eGFR 33.8 (24.0-46.6) mL/min/1.73 m2 and urine albumin to creatinine ratio 209 (33-926) mg/g; 58.5% were male. Of these participants, 1883 (69.1%) were in high-risk CKD categories. Primary renal diagnosis was CKD of unknown cause in 32.3%, glomerular disease in 23.4% and diabetic kidney disease in 11.5%. Older participants and those with lower eGFR had higher systolic blood pressure and were less likely to be treated with renin-angiotensin system inhibitors (RASi) but were more likely to receive a statin. Female participants were less likely to receive a RASi or statin. NURTuRE-CKD is a prospective cohort of persons who are at relatively high risk of adverse outcomes. Long-term follow-up and a large biorepository create opportunities for research to improve risk prediction and to investigate underlying mechanisms to inform new treatment development.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic kidney disease (CKD) is common but heterogenous and is associated with multiple adverse outcomes. The National Unified Renal Translational Research Enterprise (NURTuRE)-CKD cohort was established to investigate risk factors for clinically important outcomes in persons with CKD referred to secondary care.
METHODS
METHODS
Eligible participants with CKD stages G3-4 or stages G1-2 plus albuminuria >30 mg/mmol were enrolled from 16 nephrology centres in England, Scotland and Wales from 2017 to 2019. Baseline assessment included demographic data, routine laboratory data and research samples. Clinical outcomes are being collected over 15 years by the UK Renal Registry using established data linkage. Baseline data are presented with subgroup analysis by age, sex and estimated glomerular filtration rate (eGFR).
RESULTS
RESULTS
A total of 2996 participants was enrolled. Median (interquartile range) age was 66 (54-74) years, eGFR 33.8 (24.0-46.6) mL/min/1.73 m2 and urine albumin to creatinine ratio 209 (33-926) mg/g; 58.5% were male. Of these participants, 1883 (69.1%) were in high-risk CKD categories. Primary renal diagnosis was CKD of unknown cause in 32.3%, glomerular disease in 23.4% and diabetic kidney disease in 11.5%. Older participants and those with lower eGFR had higher systolic blood pressure and were less likely to be treated with renin-angiotensin system inhibitors (RASi) but were more likely to receive a statin. Female participants were less likely to receive a RASi or statin.
CONCLUSIONS
CONCLUSIONS
NURTuRE-CKD is a prospective cohort of persons who are at relatively high risk of adverse outcomes. Long-term follow-up and a large biorepository create opportunities for research to improve risk prediction and to investigate underlying mechanisms to inform new treatment development.
Identifiants
pubmed: 37230953
pii: 7180015
doi: 10.1093/ndt/gfad110
pmc: PMC10615633
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2617-2626Subventions
Organisme : Medical Research Council
ID : MR/R013942/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Références
Nutrients. 2021 Nov 08;13(11):
pubmed: 34836228
Nephrol Dial Transplant. 2015 Mar;30(3):441-51
pubmed: 25271006
Kidney Int. 2015 Nov;88(5):950-7
pubmed: 26221752
N Engl J Med. 2022 Dec 1;387(22):2021-2032
pubmed: 36326117
N Engl J Med. 2006 Jan 12;354(2):131-40
pubmed: 16407508
Kidney Int. 2019 Oct;96(4):983-994
pubmed: 31358344
J Am Soc Nephrol. 2022 Oct;33(10):1804-1806
pubmed: 36096636
QJM. 2013 Oct;106(10):915-24
pubmed: 23813282
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
JAMA. 2016 Jan 12;315(2):164-74
pubmed: 26757465
Kidney Int. 2019 Nov;96(5):1048-1050
pubmed: 31582227
Kidney Int. 2019 Nov;96(5):1217-1233
pubmed: 31570197
Clin Kidney J. 2019 Jun 10;13(2):199-207
pubmed: 32296525
Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11
pubmed: 19541818
Lancet. 2010 Jun 12;375(9731):2073-81
pubmed: 20483451
Clin Kidney J. 2021 Aug 13;15(1):60-69
pubmed: 35035937
J Am Soc Nephrol. 2022 Oct;33(10):1903-1914
pubmed: 35906075
Nephrol Dial Transplant. 2019 Feb 1;34(2):277-286
pubmed: 29635335
Nat Rev Nephrol. 2018 Mar;14(3):151-164
pubmed: 29355169
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
BMC Nephrol. 2017 Jan 14;18(1):23
pubmed: 28088175
BMC Fam Pract. 2013 Jun 24;14:88
pubmed: 23800117
BMC Nephrol. 2013 Jun 11;14:121
pubmed: 23758910
Kidney Int. 2011 Jul;80(1):93-104
pubmed: 21289597
Nephrol Dial Transplant. 2017 Jun 01;32(6):997-1005
pubmed: 27190381
Clin Exp Nephrol. 2010 Dec;14(6):558-70
pubmed: 20700621
Am J Pathol. 1948 Mar;24(2):275-91
pubmed: 18904643
J Psychosom Res. 1997 Jan;42(1):17-41
pubmed: 9055211
J Pain Symptom Manage. 2018 Aug;56(2):281-287
pubmed: 29729346